Edging Toward Interchangeability in Biosimilars
An impressive performance by Sandoz at the July 13 Arthritis Advisory Committee on its etanercept biosimilar application suggests progress on the learning curve towards interchangeable applications.
You may also be interested in...
Study and formulation requirements under PREA mean that interchangeability application might not be much more of a leap.
Biosimilars have turned drug development 'upside down,' where analytical confirmation outweighs clinical – a paradigm shift that must not only be embraced by the biopharmaceutical industry, but the prescribing community if US market for those products is going to be successful.
Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.